Why Argenx Se’s Soaring Valuation Is Suddenly Under Fire

Argenx Se ( (ARGX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

Argenx Se shares have come under pressure as investors question the company’s rich valuation and future cash‑flow profile, despite its strong operating momentum. Concerns over high expectations, the risks tied to early‑stage combination trials, and the threat of new competitors have made some analysts more cautious, cooling overall sentiment toward the stock. After Argenx reported strong preliminary 2025 sales of about $4.15 billion and a growing patient base, its market value climbed to roughly $50 billion, with the stock recently trading in the high‑$700s to low‑$800s. In response, analysts raised or reiterated price targets largely because Vyvgart is outperforming forecasts, supported by robust sales, better reimbursement, and an expanding treated population. The outlook was further boosted by the FDA’s acceptance of a priority supplemental BLA that could widen Vyvgart’s label, as well as several late‑stage trial readouts and new formulations expected in 2026 that could extend Argenx’s revenue runway, even as valuation and risk concerns cap enthusiasm.

More about Argenx Se

YTD Price Performance: -5.35%

Average Trading Volume: 355,564

Technical Sentiment Signal: Buy

Current Market Cap: $50.04B

For further insights into ARGX stock on TipRanks’ Stock Analysis page.

See more of today’s top stock gainers and losers.